Predictive value of proteomic markers for advanced rectal cancer with neoadjuvant chemoradiotherapy

BMC Cancer

Table 2 Clinicopathological characteristics and recurrence, according to biomarkers level in pre-nCRT sera

Variable	APOA1 (n = 91)			APOH (n = 91)			S10A8 (n = 91)			HEP2 (n = 91)			GELS (n = 91)			PZP (n = 91)			PEDF(n = 91)
Variable	Low n = 46	High n = 45	P	Low n = 46	High n = 45	P	Low n = 46	High n = 45	P	Low n = 46	High n = 45	P	Low n = 46	High n = 45	P	Low n = 46	High n = 45	P	Low n = 46	High n = 45	P
Age, years
Median	54	60	0.157	58	59.5	0.429	55	59.5	0.2286	59	58.5	0.5139	60	58	0.8310	55.46	59.26	0.0679	57.49	57.45	0.987
Range	9.9	8.19		9.91	9.53		9.827	9.509		9.83	9.62		9.792	9.708		9.98	9.169		9.818	9.687
Gender
Female	14	19	0.280	16	17	1.00	16	17	0.8292	15	18	0.5173	15	17	0.6641	10	23	0.0046	18	15	0.6641
Male	32	26		28	30		30	28		31	27		31	28		36	22		28	30
Pathological T stage
ypT0-2	13	29	0.0007	16	26	0.0361	17	25	0.0941	13	29	0.0007	12	30	0.0001	13	29	0.0007	15	27	0.0117
ypT3-4	33	16		30	19		29	20		33	16		34	15		33	16		31	18
Pathological N stage
ypN0	23	37	0.0018	30	32	0.654	29	33	0.3696	27	35	0.0717	25	37	0.0065	31	31	1.0	27	35	0.0717
ypN1-2	23	8		16	13		17	12		19	10		21	8		15	14		19	10
Pathological complete response
Yes	2	10	0.0141	6	6	1.0	4	8	0.2305	3	9	0.0695	2	10	0.0141	1	11	0.0017	4	8	0.2305
No	44	35		40	39		42	37		43	36		44	35		45	34		42	37
Recurrence at any site
Yes	9	7	1.0	8	8	1.0	4	12	0.0295	10	6	0.41	10	6	0.41	8	8	1.0	9	7	0.784
No	37	38		38	37		42	33		36	39		36	39		38	37		37	38

ISSN: 1471-2407